Effects of erlotinib therapy on $[^{11}C]$erlotinib uptake in EGFR mutated, advanced NSCLC

Idris Bahce$^{1, *}$, Maqsood Yaqub$^{2}$, Hanane Errami$^{1}$, Robert C. Schuit$^{2}$, Patrick Schober$^{3}$, Erik Thunnissen$^{4}$, Albert D. Windhorst$^{2}$, Adriaan A. Lammertsma$^{2}$, Egbert F. Smit$^{1,6}$ and N. Harry Hendrikse$^{2,5}$

Abstract

Background: In non-small cell lung cancer (NSCLC) patients off erlotinib therapy, positron emission tomography (PET) using $[^{11}C]$erlotinib distinguished epidermal growth factor receptor (EGFR) mutations from wild-type EGFR. However, tumor uptake of $[^{11}C]$erlotinib during erlotinib therapy is unknown. Therefore, the aims of this study were to evaluate tumor $[^{11}C]$erlotinib uptake in NSCLC patients both on and off erlotinib therapy, to evaluate the effect of erlotinib therapy on tumor perfusion and its correlation to tumor $[^{11}C]$erlotinib uptake, and also, to investigate simplified uptake parameters using arterial and venous blood samples.

Methods: Ten patients were to be scanned twice with a 1–2-week interval, i.e., on (E+) and off (E−) erlotinib therapy. Each procedure consisted of a low-dose CT scan, a 10-min dynamic $[^{15}O]$H₂O PET scan, and a 60-min dynamic $[^{11}C]$erlotinib PET scan with arterial and venous sampling at six time points. In patients(E+), the optimal compartment model was analyzed using Akaike information criterion. In patients(E−), the uptake parameter was the volume of distribution ($V_T$), estimated by using metabolite-corrected plasma input curves based on image-derived input functions and discrete arterial and venous blood samples. Tumor blood flow (TBF) was determined by rate constant of influx (K1) of $[^{15}O]$H₂O using the 1T2k model and correlated with $V_T$ and K1 values of $[^{11}C]$erlotinib. The investigated simplified parameters were standardized uptake value (SUV) and tumor-to-blood ratio (TBR) at 40–60 min post injection.

Results: Of the 13 patients included, ten were scanned twice. In patients(E+), $[^{11}C]$erlotinib best fitted the 2T4k model with $V_T$. In all patients, tumor $V_T$(E+) was lower than $V_T$(E−) (median $V_T$(E−) = 1.61, range 0.77–3.01; median $V_T$(E+) = 1.17, range 0.53–1.74; $P = 0.004$). Using $[^{15}O]$H₂O, five patients were scanned twice. TBF did not change with erlotinib therapy, TBF showed a positive trend towards correlation with $V_T$ and K1 values of $[^{11}C]$erlotinib. The investigated simplified parameters were standardized uptake value (SUV) and tumor-to-blood ratio (TBR) at 40–60 min post injection.

Conclusions: In patients on erlotinib in therapeutic dose, tumor $V_T$ decreases with high variability, independent of tumor perfusion. For simplification of $[^{11}C]$erlotinib PET scanning protocols, both arterial and venous TBR 40–60 min post injection can be used; however, arterial and venous TBR values should not be interchanged as venous values underestimate arterial values.

Trial registration: Registered at the Netherlands Trial Registry: NTR3670.

Keywords: NSCLC, PET, $[^{11}C]$Erlotinib, Erlotinib therapy
Background
Non-small cell lung cancer (NSCLC) therapy has entered an era of precision medicine with an ever-increasing amount of therapeutic agents directed against specific tumor targets. Positron emission tomography (PET) is sometimes used to study the pharmacokinetic behavior of these new agents and to identify patients that might be sensitive to these drugs [1]. For this, the molecularly targeting therapeutic agents are labeled with radionuclides to be used as PET tracers [2].

An important actionable target in NSCLC is the epidermal growth factor receptor (EGFR). EGFR tyrosine kinase inhibitors (TKIs), such as erlotinib, inhibit growth in tumors that thrive mainly on the EGFR pathway, such as tumors with an activating EGFR mutation (EGFRmut) [3, 4]. PET using carbon-11-labeled erlotinib, \([^{11}C]_{\text{erlotinib}}\), allowed to visualize and quantify tumor \([^{11}C]_{\text{erlotinib}}\) uptake in patients with EGFR-mutated NSCLC [1, 5, 6]. Moreover, tumor \([^{11}C]_{\text{erlotinib}}\) uptake was shown to be higher in TKI-sensitive EGFRmut tumors as compared to tumors with a wild-type EGFR, indicating that PET and \([^{11}C]_{\text{erlotinib}}\) may identify patients that are sensitive to erlotinib therapy [1].

Typically, EGFR TKI achieves a median progression-free survival of approximately 9–10 months in the first line setting [7]. Ultimately, all EGFRmut patients develop resistance to EGFR TKI during the course of treatment. Various patterns of disease progression may be observed. In many patients, only a few tumor lesions will grow, while others remain unchanged. In such oligoprogressive cases, it is unclear whether EGFR TKI therapy should be discontinued [8]. Decision management could be guided by knowledge of the residual EGFR TKI sensitivity of the tumor lesions.

PET using \([^{11}C]_{\text{erlotinib}}\) may provide a means to determine residual TKI uptake after disease progression appears, and consequently, may aid in deciding whether or not to discontinue EGFR TKI therapy. To answer this question, PET should preferably be performed during erlotinib treatment. However, thus far, \([^{11}C]_{\text{erlotinib}}\) PET scans were performed exclusively in the absence of erlotinib exposure [1, 5, 6]. To be able to interpret \([^{11}C]_{\text{erlotinib}}\) PET data of patients in this clinical setting, the effects caused by the presence of therapeutic concentrations of non-labeled erlotinib on tumor \([^{11}C]_{\text{erlotinib}}\) uptake need to be investigated first. From a tracer pharmacokinetic perspective, studying the effects of erlotinib therapy on \([^{11}C]_{\text{erlotinib}}\) metabolism, plasma concentration, and tumor uptake can improve our understanding of the tracer uptake. These pharmacokinetic insights are needed for optimization of scanning protocols and design of future TKI PET studies. At present, the literature concerning this topic is limited, and to the best of our knowledge, no other clinical trial scanned patients with a radiolabeled EGFR TKI during treatment with the same EGFR TKI.

We performed a pilot study to assess the effect of pharmacological erlotinib concentrations on tumor \([^{11}C]_{\text{erlotinib}}\) uptake. The primary objective was to compare tumor tracer uptake using the gold standard measure for \([^{11}C]_{\text{erlotinib}}\) uptake volume of distribution (\(V_T\)) in the presence and absence of pharmacological concentrations of erlotinib. The secondary aim of this study was to assess the effects of erlotinib therapy on tumor blood flow and its correlation with tumor \([^{11}C]_{\text{erlotinib}}\) uptake. In addition, for simplification of future protocols, we also investigated simplified uptake parameters, i.e., standardized uptake values (SUVs) and tumor-to-blood ratio (TBR). TBR was based on arterial samples; however, we also used venous samples. This was again important for simplification of future protocols as arterial cannulation could be omitted if venous sampling was proven to be a valid substitute.

Methods
Patients
Patients with histologically proven EGFRmut NSCLC who were either planned to initiate erlotinib therapy or to stop erlotinib therapy due to disease progression while on erlotinib were asked to participate. Key inclusion criteria were age above 18 years, life expectancy of at least 12 weeks, at least one tumor lesion with a diameter of at least 1.5 cm in the chest region as measured by CT, Karnofsky index \(\geq 60\%\), and a written informed consent. Exclusion criteria were claustrophobia, pregnancy or lactating patients, metal implants in the thorax (e.g., pacemakers) that could interfere with PET/CT imaging, and concurrent treatment with experimental drugs. The study was approved by the Medical Ethics Review Committee of the VU University Medical Center. All patients provided written informed consent prior to inclusion.

Study design
The aim was to include ten patients with EGFRmut NSCLC, who underwent two PET scan sessions. Patients who were on erlotinib therapy (E+) stopped therapy on the day of their first scan. Patients who were erlotinib naïve (E−) started therapy, immediately following the scanning procedure on day 1. For all patients, a second PET scan session was performed after 7 to 14 days. All PET scans were planned to start at the same time of the day, i.e., at 1:00 p.m. Patients on erlotinib therapy were asked to take their last medication, i.e., erlotinib 150 mg, at 8:00 a.m.

PET/CT scanning procedure
One cannula was inserted into the radial artery for arterial blood sampling and another one into a contralateral...
arm vein for tracer injection and venous blood sampling. Scans were performed on a Gemini TF-64 PET/CT scanner (Philips Medical Systems, Best, the Netherlands), which is a high performance, time-of-flight (TOF), fully three-dimensional PET scanner combined with a 64-slice Brilliance CT scanner [9]. First, 370-MBq $^{15}$O$\text{H}_2$O was injected intravenously, simultaneously starting a 10-min emission scan. Next, a low-dose CT scan (30 mAs, without contrast) was performed for attenuation correction. Subsequently, 349 ± 46 MBq of $^{11}$Cerlotinib (synthesized as previously described and corresponding to a non-pharmacological dose of approximately 16.2 µg "cold" erlotinib with ≥18.5 GBq/µmol specific activity) was injected intravenously, simultaneously starting a 60-min emission scan [1]. $^{15}$O$\text{H}_2$O and $^{11}$Cerlotinib emission scans were acquired in list-mode and reconstructed into 26 frames with progressive increase in frame duration (1 × 10, 8 × 5, 4 × 10, 2 × 15, 3 × 20, 2 × 30, and 6 × 60 s) and 36 frames (1 × 10, 8 × 5, 4 × 10, 2 × 15, 3 × 20, 2 × 30, 6 × 60, 4 × 150, 4 × 300, and 2 × 600 s), respectively. All appropriate corrections were applied for dead time, decay, random, scatter, and attenuation. Reconstruction of PET data was performed using the 3D row-action maximum-likelihood algorithm (RAMLA) with CT-based attenuation correction. The final voxel size was 4 × 4 × 4 mm³ and the spatial resolution 5–7 mm full-width at half-maximum. No corrections for patient motion were applied.

Arterial and venous samples (7 mL) were taken at six time points (i.e., at 5, 10, 20, 30, 40, and 60 min) after injection of $^{11}$Cerlotinib. For both arterial and venous samples, plasma polar $^{11}$Cerlotinib metabolites and whole blood and plasma radioactivity concentrations were measured, as described previously [1].

Data analysis
For each patient, the primary tumor was identified on the low-dose CT scan, and the tumor contours were delineated visually at the margins of the tumor on all planes where the primary tumor was visible, to generate a three-dimensional tumor volume of interest (VOI). Large blood vessels and the liver were avoided as much as possible. We did not delineate tumors on PET, as $^{11}$Cerlotinib PET uptake depends strongly on tumor characteristics (e.g., EGFR mutation). CT-based contour delineation was performed using an in-house software, developed within the interactive data language (IDL Virtual Machine 6.2, RSI Inc., Boulder, CO, USA) environment. Then, tumor VOIs were projected onto the dynamic $^{11}$Cerlotinib PET scan to generate tumor $^{11}$Cerlotinib time activity curves (TACs). In addition, metabolite-corrected image-derived plasma input functions (IDIFs) were derived from VOIs drawn on ten subsequent slices within the descending aorta (approximately 7 mL). Then, this arterial whole blood TAC was calibrated by the whole blood activity concentrations measured from the six manually drawn arterial blood samples. Next, the data was multiplied by the multi-exponential function that best fitted the plasma-to-whole blood ratios, again derived from the manual samples, to generate a plasma TAC. Then, the plasma TAC was corrected for metabolites using a sigmoid function derived from the best fit to the measured parent fractions of the arterial samples. Finally, a correction for delay was applied; this metabolite-corrected plasma TAC was used as IDIF [10–12].

A distinction was made in processing the kinetic data from patients on and off therapy. Previously, in patients off therapy, the optimal model for tumor $^{11}$Cerlotinib pharmacokinetics was found to be the reversible two-tissue model (2T4k) [1]. In patients off therapy, all tumor TACs were analyzed using this model. It was unknown, however, whether the same model was also valid for patients on erlotinib therapy. Therefore, in the latter patients, first, the optimal model was identified by fitting tumor $^{11}$Cerlotinib TACs to three conventional compartment models (i.e., single tissue, irreversible two-tissue, and reversible two-tissue) [10]. Subsequently, the optimal model was chosen on the basis of the Akaike information criterion [13]. After establishing the optimal model for patients on erlotinib therapy, all tumor TACs were analyzed using the corresponding preferred model. Pharmacokinetic analysis and modeling of tumor TACs and IDIF was performed using in-house software, developed within MATLAB (MathWorks, Inc).

In order to understand the effects of metabolism on $V_T$ values under erlotinib therapy, the change in tumor $V_T$ was correlated with the level of metabolism. As the level of metabolism, the parent fraction measured at 40 and 50 min. In addition, TBR values were evaluated using both arterial and venous whole blood activity concentrations in the time interval 40–50 and 50–60 min. These intervals were chosen, as unpublished analysis of previous scans showed that TBR using whole blood activity between 40 and 60 min correlated best with $V_T$ [1].

Simplified analyses
Accuracies of several simplified static approaches were evaluated. SUVs, normalized for patient weight and injected dose, were evaluated in the interval 40–50 and 50–60 min. In addition, TBR values were evaluated using both arterial and venous whole blood activity concentrations in the time interval 40–50 and 50–60 min. These intervals were chosen, as unpublished analysis of previous scans showed that TBR using whole blood activity between 40 and 60 min correlated best with $V_T$ [1].
Statistical analysis
Statistical analysis was performed using SPSS software (SPSS for Windows 20.0, SPSS, Inc., Chicago, USA) and GraphPad (GraphPad Prism version 5.00 for Windows, GraphPad Software, San Diego, CA, USA). Spearman’s correlation coefficient (r_s) and simple linear regression were used for correlations. A two-tailed probability value of P < 0.05 was considered to be significant. Bland-Altman analysis was performed to assess agreement between venous TBR and arterial TBR, between TBR_{40–50} and TBR_{50–60} and between venous and arterial tracer parent fractions. The Wilcoxon matched-pairs signed-rank test was used to test differences between scans with and without erlotinib therapy regarding V_T values, parent fraction values, whole blood SUVs, and TBF values. This test was also used to assess differences between whole blood SUVs obtained with arterial and venous samples.

Results
Patient characteristics
Patient characteristics are shown in Table 1. As three patients could only be scanned once, a total of 13 patients were recruited in order to obtain ten patients who were scanned twice using [^{11}C]erlotinib. In nine out of these ten patients, both quantitative kinetic analyses could be obtained. In the remaining patient, this was not possible due to technical problems with blood sampling. In seven out of nine evaluable patients, the first [^{11}C]erlotinib PET scan was without erlotinib therapy. In the remaining two out of nine patients, the first scan was performed while receiving erlotinib therapy. In only five out of nine evaluable patients, both [^{15}O]H_2O TBF(E−) and TBF(E+) could be derived. In the remaining patients, data from both [^{15}O]H_2O PET scans could not be performed or analyzed due to technical problems, as indicated in Table 1.

Effects of erlotinib therapy on plasma kinetics
Parent fractions of [^{11}C]erlotinib, as measured in arterial plasma samples, were higher in patients on therapy at all time points (all P values <0.05, see Fig. 1a). Change in tracer metabolism during erlotinib therapy did not correlate with changes in V_T (r_s = 0.33, P = 0.385), as shown in Fig. 1b.

Arterial blood activity, normalized to injected dose and patient weight, was also higher in patients on therapy at all time points (all P values <0.05, Fig. 1c). Detailed results are shown in Additional file 1: Tables S1 and S2.

Effects of erlotinib therapy on kinetic modeling and tumor [^{11}C]erlotinib uptake
According to the Akaike information criterion, the reversible two-tissue compartment model (2T4k) was the preferred model in all patients(E+). This was also the case for patients(E−), confirming previous findings [1, 5, 6]. In all nine evaluable patients, tumor [^{11}C]erlotinib V_T(E+) was significantly lower than V_T(E−) with a mean (±SD) intra-patient decrease of 38 ± 13 % (median V_T(E−) = 1.61, range 0.77–3.01; median V_T(E+) = 1.17, range 0.53–1.74; P = 0.004; see Fig. 2a). There was a good correlation between V_T(E+) and V_T(E−) (r_s = 0.82; P = 0.011), as shown in Fig. 2b. See Additional file 1: Table S3 for detailed results.

Effects of erlotinib therapy on tumor [^{15}O]H_2O perfusion
Tumor [^{15}O]H_2O perfusion did not change between patients on (N = 8) and off (N = 8) erlotinib therapy (with a mean ± SD TBF of 0.475 ± 0.194 and 0.622 ± 0.397 mL/cm^2/min, P = 0.813, respectively, see Fig. 3a). There was no correlation between TBF and [^{11}C]erlotinib V_T in patients(E−) and patients(E+) (r_s = 0.452, P = 0.268 and r_s = 0.167, P = 0.703, respectively, see Fig. 3b). Tumor rate constant of [^{11}C]erlotinib influx, i.e., K_1, showed a trend towards positive correlation with TBF(E−) and TBF(E+); however, this was not statistically significant (r_s = 0.714, P = 0.058 and r_s = 0.405, P = 0.327, respectively, see Fig. 3c) (see Additional file 1: Table S4 for detailed results).

Effects of erlotinib therapy on simplified uptake parameters
SUVs did not correlate with V_T values, both on and off erlotinib therapy (r_s = 0.39, P = 0.260 and r_s = 0.30, P = 0.342, respectively). However, TBR_{40–50} values showed good correlation with V_T values, both on and off therapy (r_s = 0.97, P < 0.001 and r_s = 0.96, P < 0.001, respectively), as shown in Fig. 4. TBR_{50–60} also showed good correlation with V_T versus patients(E−) (r_s = 0.92, P < 0.001 and r_s = 0.99, P < 0.001, respectively). The mean (±SD) difference between TBR_{50–50} and TBR_{50–60} in patients off therapy was 4 ± 7 % and 1 ± 7 % in patients on therapy.

Representative parametric [^{11}C]erlotinib images, using TBR_{50–60}, of a typical patient off and on erlotinib therapy are shown in Fig. 5.

Arterial versus venous whole blood activity
The mean venous blood activity values, normalized to injected dose and patient weight, were higher than the mean arterial values for all measured time points in patients(E−) (P < 0.05). In patients(E+) at 5 min post injection, the venous values were significantly higher than arterial values, and at the remaining time points, no difference was observed. Figure 6a illustrates the mean ± SD whole blood SUV obtained from venous and arterial samples, in patients off and on erlotinib therapy.

Arterial versus venous metabolites
Metabolite analyses showed a good correlation between arterial and venous samples (r_s = 0.91, P < 0.001
| Number | Gender, age (years) | EGFR mutation (TKI sensitivity) | Response to erlotinib | ¹¹C]Erlotinib PET scans | Condition | Arterial sampling | Venous sampling | [¹⁵O]H₂O PET scans | Remarks |
|--------|---------------------|---------------------------------|---------------------|--------------------------|-----------|------------------|----------------|------------------|---------|
|        |                     |                                 | (sensitive + resistant) | First scan | E+ | Yes | Yes | Yes | Synthesis of [¹¹C]erlotinib failed quality check |
|        |                     |                                 | 60                  | Second scan | E− | NA | NA | NA | |
| 2      | F                   | exon19 (p.delE746-A750)         | 60                  | First scan | E− | Yes | Yes | Yes | No venous sampling due to clogging of the venous cannula |
|        |                     |                                 | 82                  | Second scan | E+ | Yes | NA | Yes | |
|        | M                   | exon18 (p.G719S and p.E709A)    | 74                  | First scan | E− | Yes | Yes | Yes | Synthesis of [¹⁵O]H₂O failed quality check |
|        |                     |                                 | (sensitive) [22, 23] | Second scan | E+ | Yes | Yes | NA | |
| 4      | M                   | exon21 (p.P848L)                | 66                  | First scan | E− | Yes | Yes | Yes | |
|        |                     |                                 | (resistant [24]) | Second scan | E+ | Yes | Yes | Yes | |
| 5      | F                   | exon19 (p.delE746-T751) (sensitive) | 61                  | First scan | E+ | Yes | Yes | NA | Synthesis of [¹⁵O]H₂O failed quality check |
|        |                     |                                 |                    | Second scan | NA | NA | NA | NA | Yield of [¹¹C]erlotinib synthesis too low |
| 6      | F                   | exon19 (p.delE746-A750) and exon20 (p.T790M) | 45                  | First scan | E+ | Yes | Yes | Yes | |
|        |                     | Slow PD                         | 45                  | Second scan | E− | Yes | Yes | Yes | |
| 7      | M                   | exon19 (p.E746-S752) and exon20 (p.T790M) | 74                  | First scan | E− | NA | NA | NA | Aberrant arterial and venous blood sample values |
|        |                     | (sensitive + resistant)          | 74                  | Second scan | E+ | Yes | Yes | Yes | Aberrant [¹⁵O]H₂O PET data |
| 8      | M                   | exon18 (p.G719S) and exon20 (p.S768I) | 81                  | First scan | E− | Yes | Yes | Yes | |
|        |                     | (unclear [25, 26, 27])          | 81                  | Second scan | E+ | Yes | Yes | Yes | |
|     | Sex | Exon Characteristics | Tumor Stage | Tumor Response (E+) | Tumor Response (E−) | Target Ki-1829 Synthesis | Target Ki-1829 Synthesis | Ki-1829 Synthesis | Remarks |
|-----|-----|----------------------|-------------|---------------------|---------------------|--------------------------|--------------------------|----------------------|---------|
| 9   | F   | exon19 (p.delE746-A750) | PR          | First scan          | E−                  | Yes                      | Yes                      | Yes                  | Aberrant [18O]H2O PET data |
|     |     | (sensitive)           |             |         -29 %         |         Second scan  | E+                      | Yes                      | Yes                  |         |
| 10  | F   | exon19 (p.delE746-S752 and p.F753Q) and exon2 (p.T790M) | Slow PD     | First scan          | E+                  | Yes                      | Yes                      | NA                   | No [18O]H2O synthesis |
|     |     | (sensitive + resistant) |             |         -25 %         |         Second scan  | E−                      | Yes                      | Yes                  |         |
| 11  | F   | exon21 (p.L851Q)      | SD          | First scan          | E−                  | Yes                      | Yes                      | Yes                  | No [18O]H2O synthesis |
|     |     | (sensitive [28])      |             |         -39 %         |         Second scan  | E+                      | Yes                      | Yes                  |         |
| 12  | M   | exon19 (p.delE746-S752) | PR          | First scan          | E−                  | Yes                      | Yes                      | Yes                  | Yield of [11C]erlotinib synthesis too low |
|     |     | (sensitive)           |             |         -            |         Second scan  | NA                      | NA                      | NA                   |         |
| 13  | F   | exon21 (p.L858R) and exon2 (p.T790M) | Slow PD    | First scan          | E−                  | Yes                      | Yes                      | Yes                  |         |
|     |     | (sensitive + resistant) |             |         -40 %         |         Second scan  | E+                      | Yes                      | Yes                  |         |

Abbreviations: F female, M male, E+ with erlotinib therapy, E− without erlotinib therapy, CR complete response, PR partial response, SD stable disease, PD progressive disease, NA not available

*Tumor response to erlotinib as evaluated at the time of the first scan (in patients stopping erlotinib) or tumor response to erlotinib after its initiation (in patients starting erlotinib therapy)

*Change in VT as defined by (VT(E+))−VT(E−))/VT(E−)
and $r_s = 0.76$, $P < 0.001$) in patients(E−) and patients(E+), respectively. There was a good agreement between arterial and venous parent fractions, both off and on erlotinib therapy (with an average ($\pm$SD) bias of $-4.8 \pm 4.6$ and $-0.7 \pm 3.5$ %, respectively, see Fig. 6c, d).

**Arterial versus venous TBR**

Only eight out of nine evaluable patients had arterial and venous sampling in both conditions, i.e., with and without erlotinib therapy. TBR$_{40-50}$ values obtained using arterial and venous blood samples showed good correlation with each other, both off ($r_s = 0.95$, $P < 0.001$) and on ($r_s = 0.83$, $P = 0.002$) erlotinib therapy. Similar results were obtained with TBR$_{50-60}$ (with $r_s$ (E−) = 0.89, $P < 0.001$ and $r_s$ (E+) = 0.93, $P < 0.001$).

Venous sampling underestimated TBR$_{40-50}$ as compared to arterial sampling in patients(E−) and patients(E+) by an average ($\pm$SD) of $26 \pm 12$ and $9 \pm 9$ %, respectively (see Fig. 6c, f). However, venous TBR did have a good correlation with arterial $V_T$ ($r_s$ (E−) = 0.90, $P < 0.001$ and $r_s$ (E+) = 0.79, $P = 0.006$), as shown in Fig. 4d (see Additional file 1: Table S5 for individual results).

**Fig. 1** Effect of erlotinib therapy on parent fractions. Comparison of mean ($\pm$SD) arterial parent fractions of $[^11]$Cerlotinib with and without erlotinib therapy (a). Correlation of $V_T$ change and arterial parent fractions change at 60 min post injection (b). Arterial blood SUV, i.e., activity normalized to injected dose and patient weight, in patients off and on therapy (c). Abbreviations: $V_T$ volume of distribution, SUV standardized uptake value, E− without erlotinib therapy, E+ with erlotinib therapy.

**Fig. 2** Tumor $V_T$ values. $V_T$ values of all patients without and with erlotinib therapy (a). Correlation between $V_T$ with and $V_T$ without erlotinib therapy (b). Abbreviations: $V_T$ volume of distribution, E− without erlotinib therapy, E+ with erlotinib therapy.
Fig. 3 Tumor blood flow. TBF values of patients without (N = 8) and with (N = 8) erlotinib therapy (a). Correlation of tumor perfusion (TBF) with $V_T$ (b) and $[^{11}C]$erlotinib $K_1$ (c). Abbreviations: TBF tumor blood flow, $V_T$ volume of distribution, E– without erlotinib therapy, E+ with erlotinib therapy, $K_1$ influx rate constant

Fig. 4 Simplified uptake parameters. TBR values from the 40–50-min post injection interval, using arterial samples (a) and SUVs from the 40–50-min post injection interval (b) in all patients off and on erlotinib therapy. Correlation between TBR values from the 40–50-min post injection interval, using arterial (c) and venous (d) samples, with $V_T$ in all patients off and on erlotinib therapy. Abbreviations: TBR tumor-to-blood ratio, SUV standardized uptake value, $V_T$ volume of distribution, E– without erlotinib therapy, E+ with erlotinib therapy.
Discussion

Effects of erlotinib therapy on tumor tracer uptake

The present study demonstrated that tumor $^{11}$C-erlotinib $V_T$ decreases significantly during erlotinib therapy.

To our best knowledge, this is the first clinical study that investigated the change of radiolabeled EGFR TKI uptake in patients off and on treatment using the same EGFR TKI. In the presence of therapeutic concentrations of erlotinib, tumor $^{11}$C-erlotinib uptake decreased. This was presumably caused by occupancy of EGF receptors by abundantly present non-labeled erlotinib, i.e., due to a decrease in available binding sites. Blocking studies in xenograft models provide support for this mechanism. Using $^{11}$C-erlotinib, Petrulli et al. showed that NSCLC xenografts with activating EGFRmut (HCC827) in mice had lower tracer uptake when cold erlotinib was given along with the tracer [16]. In addition, Abourbeh et al. showed in mice-bearing HCC827 xenografts more than 50 % reduction in tumor $^{11}$C-erlotinib uptake after administration of excess non-labeled erlotinib [17]. Similar results were obtained with other radiolabeled TKI, such as $^{18}$F-afatinib [18] and $^{11}$C-PD153035 [19]. The fact that there was consistent decrease in $^{11}$C-erlotinib uptake in the present study supports the notion that uptake of $^{11}$C-erlotinib is, at least in part, due to specific binding. Furthermore, in the presence of therapeutic concentrations of erlotinib, obtained by taking a fixed oral dose of 150 mg erlotinib daily, there was still residual tumor tracer uptake. Interestingly, from a pharmacokinetic perspective, this may indicate that there may be room for increasing the therapeutic concentration of erlotinib, as at maximal concentration, the specific binding would be absent.

Erlotinib therapy is known to induce metabolizing enzymes, such as CYP1A, CYP3A4, and CYP3A5 [20]. Also, in vitro data suggest that erlotinib stimulates the metabolism of midazolam in human microsomes, suggesting that erlotinib could induce its own metabolism and thus also increase the clearance of $^{11}$C-erlotinib [21]. However, this was not observed in the present study. On the contrary, parent fractions at 60 min post injection were significantly higher during erlotinib therapy. Possibly, the presence of abundant non-labeled erlotinib also saturated the metabolizing enzymes, thereby slowing down the metabolism of $^{11}$C-erlotinib. Moreover, patients on therapy had higher blood activity concentrations, normalized to injected dose and patient weight. This may also be caused by higher concentrations of circulating parent tracer due to the blocking of receptors and enzymes by high concentrations of non-labeled erlotinib.
Among the nine evaluable patients, two were scanned first under erlotinib therapy and stopped therapy immediately thereafter. In these two patients, the abovementioned findings were also true, i.e., $V_T(E^+) < V_T(E^-)$ and metabolites($E^+$) were lower than metabolites($E^-$). This supports the notion that the presence of non-labeled erlotinib determined these pharmacokinetic changes by the abovementioned mechanism.

High tumor sensitivity to erlotinib could potentially cause a large decrease in $V_T$. Namely, in the absence of cold erlotinib, EGFR-TKI-sensitive tumors are expected to have high $[^{11}C]$erlotinib $V_T$ values as compared to resistant tumors [1]. Once cold erlotinib is added, EGF receptors become blocked causing $V_T$ to drop. The results of this study confirmed that the patients with the largest decrease in $V_T$ did have responsive tumors; however, there was no clear association between decrease in $V_T$ and tumor response. To illustrate, three patients (patients 8, 2, and 6) had a large (i.e., approximately 50 %) decrease in $V_T$. Patient 8 was treated with erlotinib therapy for a few weeks only. Erlotinib was stopped, as he refused to continue therapy due to a pneumonia that he ascribed to erlotinib. He did have some tumor regression with erlotinib during these few weeks, however, not enough to be declared a partial response. Patient 2 had a complete response to erlotinib therapy after 3 months. Patient 6 had a slow disease progression prior to erlotinib scanning; she stopped erlotinib therapy after her first...
scan but developed a severe flare of her disease within 1 week. Her second scan showed increased tumor volume and increased $V_T$; this illustrates that her tumor still had significant amount of sensitive clones. These cases demonstrate that high decrease in $V_T$ can occur in sensitive tumors; however, there was no clear association, that is, responders did not exclusively show high decrease, as there were two other cases with partial tumor response to erlotinib therapy who showed moderate decrease in $V_T$ of 29 and 17%. On the other hand, as a result of erlotinib therapy, changes can occur in the size of the tumor, its concentration of vital tumor cells and possibly its EGFR density. These changes can occur in a period as short as 7 to 14 days after initiation or discontinuation of therapy and may also influence $V_T$. Therefore, any tumor response to erlotinib therapy may also influence the decrease of $V_T$ during therapy. However, the limited number of patients scanned does not allow for extensive elaboration. Future studies including more patients should investigate the correlation between response and change in uptake.

The decrease in $V_T$ varied between 17 and 58%. This high level of variability disqualifies $V_T(E+)$ as substitute for $V_T(E−)$. Any quantitative comparison between patients or between different time points in a single patient should be performed using $V_T(E−)$. However, for intra-patient interlesional comparison at a single time point, $V_T(E+)$ may still be considered. Whether tumor TKI sensitivity can be predicted by $^{[1]}{C}e$rlotinib $V_T(E+)$ remains to be investigated.

**Effect of erlotinib therapy on tumor perfusion**

Tumor perfusion was not changed by erlotinib treatment. Also, tumor perfusion showed no association with $^{[1]}{C}e$rlotinib $V_T(E−)$ nor with $V_T(E+)$. However, there was a positive trend between tumor perfusion and the delivery of $^{[1]}{C}e$rlotinib to the tumor, which is in accordance with the 2T4k model. These findings suggest that the extraction of $^{[1]}{C}e$rlotinib remains unchanged during erlotinib therapy.

**Simplified uptake parameters**

For simplification of future scanning protocols, SUV was not found to be a suitable uptake parameter, as it did not correlate with $V_T$, both on and off therapy. SUV normalizes on the basis of injected dose and patient weight, which is less accurate as compared to TBR that normalizes on the basis of the blood pool activity itself. For example, during erlotinib therapy, the blood tracer concentrations were higher. Due to this increased tracer availability, the absolute amount of tumor tracer binding may have changed in varying extent. Tumor SUV does not take this variable into account, whereas TBR does. Contrary to SUV, arterial and venous TBR showed an excellent correlation with arterial $V_T$, supporting the use of both arterial and venous TBR in the time interval of 40 to 60 min post injection in future whole body static scanning protocols.

Interestingly, venous TBR values were lower than the arterial TBR values, especially in patients off therapy. This was due to higher plasma activity in venous samples than in arterial samples. As no difference in metabolism was observed between venous and arterial samples, the higher venous plasma activity values were only caused by a higher venous concentration of parent molecules. The reason for this finding is unclear. Possibly, the interstitial compartment together with EGFR molecules that are highly expressed at the epidermal tissue compartment act as a capacitor, by reversibly binding $^{[1]}{C}e$rlotinib molecules. So, venous plasma collects not only the unbound $^{[1]}{C}e$rlotinib molecules coming from the arterio-capillary route but also the $^{[1]}{C}e$rlotinib molecules being released from the interstitial and peripheral tissue compartments. This can also explain why patients on therapy, who have more EGFR saturation, have less veno-arterial activity difference. Another cause that may be considered is the fact that a single venous cannula was used for tracer injection and blood withdrawal, which implies that venous activity may increase due to the presence of tracer molecules that remained sticking to the cannula wall during injection. However, this mechanism is unlikely as it cannot explain why the veno-arterial difference was higher in off therapy than on therapy. Nevertheless, venous sampling was found to be suitable for interlesional quantitative comparison using TBR, as long as venous values are not interchanged together with arterial values.

**Limitations**

This study was limited by the fact that not all uptake values of $^{[1]}{C}e$rlotinib and $^{[18]}{O}H_2O$ and not all arterial and venous sampling values were present or evaluable in all patients; this was due to practical limitations as mentioned in Table 1. The small number of patients did not allow to establish the clinical role of $^{[1]}{C}e$rlotinib PET during erlotinib therapy. Larger studies are needed to explore the clinical benefits of scanning during therapy, e.g., for evaluating interlesional differences within a single patient, preferably using TBR as validated in the current study.

**Conclusions**

Therapeutically dosed oral erlotinib decreases tumor $^{[1]}{C}e$rlotinib $V_T$ with high variability, independent of tumor perfusion. In patients on erlotinib therapy, quantitative tracer uptake analysis using $V_T$ does not seem appropriate; however, it may be useful for intrapatient comparison of tumor lesions, which remains to be
investigated. For protocol simplification, both arterial and venous TBR, in the time interval between 40 and 60 min post injection, could be used; however, arterial and venous TBR values should not be interchanged as venous values underestimate arterial values.

### Additional file

**Additional file 1:** Supplementary data. Table S1. Parent fractions (%).
Table S2. Whole blood SUV. Table S3. Tumor $^{18}$F-F4-N-(3-bromoanilino)-6, 7-dimethoxyquinazoline as a positron emmission tomography for in vivo evaluation of EGFR receptor mutational status. Clin Cancer Res. 2013;19:183–93.

### Abbreviations

CT: computed tomography; E–: without erlotinib therapy; E+: under erlotinib therapy; EGFR: epidermal growth factor receptor; IDIF: image-derived input function; K1: rate constant of influx; NSCLC: non-small cell lung cancer; PET: positron emission tomography; r: Spearman’s correlation coefficient; TAC: time-activity curve; TBF: tumor blood flow; T(60): tyrosine kinase inhibitor; VOI: volume of interest; V1: volume of distribution.

### Competing interests

The authors declare that they have no competing interests.

### Authors’ contributions

IB participated in the design of the study, the recruitment of patients, the collection and processing of data, the interpretation, and drafting of the manuscript. MY participated in the processing of the data and the drafting of the manuscript. AL, ES, and HH participated in the collection of data, statistical analysis, and drafting of the manuscript. PS participated in the collection of data, the interpretation, and drafting of the manuscript. All authors read and approved the final manuscript.

### Funding

Financial support was provided by a grant from the Dutch Cancer Society (KWF, project VU 2012-5550).

### Author details

1. Department of Pulmonary Diseases, VU University Medical Center, PO Box 7057, 1007MB Amsterdam, The Netherlands.
2. Department of Radiology & Nuclear Medicine, VU University Medical Center, Amsterdam, The Netherlands.
3. Department of Anesthesiology, VU University Medical Center, Amsterdam, The Netherlands.
4. Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands.
5. Department of Clinical Pharmacology & Pharmacy, VU University Medical Center, Amsterdam, The Netherlands.
6. Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.

### Received

1 November 2015 Accepted: 29 January 2016

Published online: 09 February 2016

### References

1. Bahce I, Smit EF, Lubberink M, van der Veldt AAM, Yaqub M, Windhorst AD, et al. Development of $^{11}$C-erlotinib positron emission tomography for in vivo evaluation of EGFR receptor mutational status. Clin Cancer Res. 2013;19:183–93.
2. Mammatas LH, Verheul HM, Hendrikse NH, Yaqub M, Lammertsma AA, Menke-van der Houven CW, et al. Molecular imaging of targeted therapies with positron emission tomography: the visualization of personalized cancer care. Cell Oncol. 2015;38:49–64.
3. Sharma SV, Bell DW, Selvamani J, Haber DA. Epidermal growth factor receptor mutant receptors in lung cancer. Nat Rev Cancer. 2007;7:169–81.
4. Keedy VL, Temin S, Somerset FR, Beasley MB, Johnson DH, McShane LM, et al. American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer concerning first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol. 2011;29:2121–7.
5. Weber B, Winterdahl M, Memon A, Sorensen BS, Keiding S, Sorensen L, et al. Erlotinib accumulation in brain metastases from non-small cell lung cancer: visualization by positron emission tomography in a patient harboring a mutation in the epidermal growth factor receptor. J Thorac Oncol. 2011;6:1287–9.
6. Memon AA, Weber B, Winterdahl M, Jakobsen S, Meldgaard P, Madsen HHT, et al. PET imaging of patients with non-small cell lung cancer employing an EGFR receptor targeting drug as tracer. Br J Cancer. 2011;105:1850–5.
7. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947–57.
8. Van Assche K, Ferdinande L, Lievens Y, Vandecasteele K, Sumont V. EGFR mutation positive stage IV non-small-cell lung cancer: treatment beyond progression. Front Oncol. 2014;4:350.
9. Suntt S, Kuhn A, Werner ME, Perkins AE, Kolhammer J, Karp JS. Performance of Philips Gemini TF PET/CT scanner with special consideration for its time-of-flight imaging capabilities. J Nucl Med. 2007;48:471–80.
10. Gunn RN, Gunn SR, Cunningham VJ. Positron emission tomography compartmental models. J Cereb Blood Flow Metab. 2001;21:635–52.
11. Lammert AA, Bench CJ, Hume SP, Osman S, Gunn K, Brooks DJ, et al. Comparison of methods for analysis of clinical [11C]Cracopride studies. J Cereb Blood Flow Metab. 1996;16:42–52.
12. Watabe H, Iokma Y, Kimura Y, Naganawa M, Shidahara M. PET kinetic analysis—compartmental model. Ann Nucl Med. 2006;20:583–8.
13. Akoike. A new look at the statistical model identification. IEEE Trans Autom Control. 1974;19:716–23.
14. Van der Veldt AAM, Hendrikse NH, Harms JH, Comans EFI, Postmus PE, Smit EF, et al. Quantitative parametric perfusion images using $^{18}$F-labeled water and a clinical PET/CT scanner: test-retest variability in lung cancer. J Nucl Med. 2010;51:1684.
15. Iqbal R, Kramer GM, Verwer EE, Huisman MC, De Langen AJ, Bahce I, et al. Multiparametric analysis of the relationship between tumor hypoxia and perfusion using $^{18}$F-FAZA and $^{18}$F-H2O PET. J Nucl Med. 2015;66:115–21.
16. Petroull JR, Sullivan JM, Zheng MQ, Bennett DC, Charet J, Huang Y, et al. Quantitative analysis of [11C]-erlotinib PET demonstrates specific binding for activating mutations of the EGFR kinase domain. Neoplasia. 2013;15:1347–53.
17. Abourbeh G, Itamar B, Salnikov O, Belslov S, Mishani E. Identifying erlotinib-sensitive non-small cell lung carcinoma tumors in mice using [11C] erlotinib PET. EJNMMI Res. 2015;5:4.
18. Slobbe P, Windhorst AD, Stigter-van Walsum M, Smit EF, Niessen HG, Solca F, et al. A comparative PET imaging study with the reversible and irreversible EGFR tyrosine kinase inhibitors [11C]erlotinib and [11F]eflunib in lung cancer-bearing mice. EJNMMI Res. 2015;5:14.
19. Wang H, Yu J, Yang G, Song X, Sun X, Zhao S, et al. Assessment of [11C]-labeled-4-N-(3-bromoanilino)-6, 7-dimethoxyquinazoline as a positron emission tomography agent to monitor epidermal growth factor receptor expression. Cancer Sci. 2009;98:1413–6.
20. Landheert NA, Naken LM, Schellens JH, Beijnen JH, Steeghs N, Huijema AT. Plasma concentrations of tyrosine kinase inhibitors imatinib, erlotinib, and sunitinib in routine clinical outpatient cancer care. Thier Drug Monit. 2014;36:326–34.
21. Li J, Zhao M, He P, Hidalgo M, Baker SD. Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin Cancer Res. 2007;13:731–7.
22. Pao W, Chmielecki J. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer. 2010;10:760–74.
23. Riely GJ, Politi KA, Miller VA, Pao W. Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin Cancer Res. 2006;12:2322–41.
24. Han B, Zhou X, Zhang R-X, Song H-D, Chen Z-Y, Song H-D, et al. Mutations of the epidermal growth factor receptor gene in NSCLC patients. Oncol Lett. 2011;2:1233–7.
25. Arcila ME, Nafa K, Chaft JE, Rekhtman N, Lau C, Reva BA, et al. EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics. Mol Cancer Ther. 2013;12:220–9.
26. Wu J-Y, Wu S-G, Yang C-H, Gow C-H, Chang Y-L, Yu C-J, et al. Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response. Clin Cancer Res. 2008;14:4877–82.
27. Masago K, Fujita S, Irisa K, Kim YH, Ichikawa M, Mio T, et al. Good clinical response to gefitinib in a non-small cell lung cancer patient harboring a rare somatic epidermal growth factor gene point mutation; codon 768 AGC > ATC in exon 20 (S768I). Jpn J Clin Oncol. 2010;40:1105–9.

28. Ong M, Kwan K, Kamel-Reid S, Vincent M. Neoadjuvant erlotinib and surgical resection of a stage IIa papillary adenocarcinoma of the lung with an L861Q activating EGFR mutation. Curr Oncol. 2012;19:e222.